Supernus Pharmaceuticals (SUPN)
(Delayed Data from NSDQ)
$33.65 USD
+1.26 (3.89%)
Updated Aug 13, 2024 03:59 PM ET
After-Market: $33.64 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Price, Consensus and EPS Surprise
SUPN 33.65 +1.26(3.89%)
Will SUPN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SUPN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SUPN
Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?
Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say
SUPN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates
Select Medical (SEM) Q2 Earnings and Revenues Top Estimates
Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?
Other News for SUPN
Piper Sandler Reaffirms Their Buy Rating on Supernus Pharmaceuticals (SUPN)
Supernus: Q2 Earnings Snapshot
Supernus Announces Second Quarter 2024 Financial Results
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2024 Earnings Call Transcript
Here is the next potential market catalyst